West Pharmaceutical Services, Inc. ( WST ) shares surged Thursday after the company's first-quarter 2026 earnings surpassed analyst estimates.

The injectable solutions company reported adjusted earnings of $2.13 per share, beating the consensus of $1.68.

Net sales of $844.90 million increased 21% year over year, with organic growth was 15.3%, beating the consensus of $779.97 million.

Proprietary Products sales of $694.3 million grew by 23.3% and increased 17.5% on an organic basis.

HVP components, which represents 48% of the company’s total net sales, continue to be the key growth driver.

Oral GLP-1 Trend Expands Market Opportunity

HVP components grew 23% on an organic basis, led by strong performance in both GLP-1 and GLP non-GLP1 revenues.

GLP1 revenues grew significantly and contributed 10% of total company sales.

The company also noted that though it is still early days in the adoption of orals, the trend is playing out as expected, and that oral GLP-1’s are expanding the market.

West Vantage Segment (Contract-Manufactured Products) sales reached $150.6 million, up 11.6% and 6.2% on an organic basis.

Management Highlights Strong Demand And Strategic Focus

Eric Green, President, CEO, and Chair of the Board, commented: “I am pleased to report a very strong start to the year with revenues and adjusted EPS exceeding expectations. Our revenues grew 15% organically, driven by our High Value Products Components business with double-digit growth in both GLP-1 and non-GLP-1 revenues. The better-than-expected performance can be attributed to continued market demand…”

The company’s strategic focus on biologics, GLP1s, Annex 1 conversions, and leveraging global infrastructure remains a priority for sustained growth.

Management expressed optimism about the future, despite macroeconomic uncertainties, and emphasized ongoing efforts to mitigate rising costs through operational efficiencies.

During the quarter, the board of directors authorized a new $1 billion share repurchase program, given the strong financial position.

West Pharmaceutical Raised Guidance Signals Continued Momentum

The company increased its fiscal 2026 guidance on excellent first-quarter results and expected continued momentum in business.

West Pharmaceutical raised its fiscal 2026 adjusted earnings per share guidance from $7.85-$8.20 to $8.40-$8.75 compared to the consensus of $8.01.

The company revised 2026 sales guidance from $3.22 billion-$3.28 billion to $3.29 billion-$3.35 billion, versus the Wall Street estimate of $3.25 billion.

WST Price Action: West Pharmaceutical shares were up 10.50% at $306.08 at the time of publication on Thursday, according to Benzinga Pro data.

Image via Shutterstock